Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians

被引:13
作者
Chan, Alexandre [1 ,2 ]
Yap, Kevin Yi-Lwern [3 ]
Koh, Dorothy [1 ]
Low, Xiu Hui [1 ]
Cheung, Yin Ting [1 ]
机构
[1] Natl Univ Singapore, Dept Pharm, Fac Sci, Singapore 117543, Singapore
[2] Natl Canc Ctr Singapore, Dept Pharm, Singapore, Singapore
[3] Univ Warwick, Inst Digital Healthcare, WMG, Coventry CV4 7AL, W Midlands, England
关键词
oral anticancer drugs; antidepressants; drug-drug interactions; prevalence; co-prescription; TAMOXIFEN; CHEMOTHERAPY; INHIBITORS;
D O I
10.1002/pds.2167
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Electronic drug interaction databases are often utilized in clinical practice to detect for possible drug-drug interactions between drug pairs. It is uncertain, however, whether most of these detections interactions are clinically important in practice. To demonstrate these issues, this study utilized a comprehensive drug-drug interaction( DDI) electronic database to elucidate the prevalence of DDIs at a cancer centre between antidepressants and oral anticancer drugs( ACDs). Methods Drug utilization reports were retrieved to determine the patients who were prescribed with antidepressants oral ACDs between 2006 and 2009 at a cancer center. Medication records of these patients were retrospectively examined using OncoRx, an internet-based oncology-specific database that allows the identification of DDIs. Results Out of 910 users of antidepressants, about one-third( 281 patients, 30.9%) used an oral ACD and an antidepressant concomitantly. From these patients, about one-fifth( 21.0%) had potential DDIs. These patients were users of 17 potentially interacting drug pairs. Ten out of the 17 drug pairs could potentially cause pharmacokinetic interactions, and the rest were pharmacodynamic interactions, with only three out of the 17 drug pairs were clinically documented to cause interacting events. Conclusion The lack of screening conditions may have led to an over detection of DDI combinations by electronic DDI databases. Many of the detected interactions may not deem high significance in clinical practice. This study exposed a major weakness of current electronic DDI databases for detecting oral ACDs and antidepressants DDIs. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:939 / 947
页数:9
相关论文
共 28 条
[1]   Antidepressant prescribing in community cancer care [J].
Ashbury, FD ;
Madlensky, L ;
Raich, P ;
Thompson, M ;
Whitney, G ;
Hotz, K ;
Kralj, B ;
Edell, WS .
SUPPORTIVE CARE IN CANCER, 2003, 11 (05) :278-285
[2]  
*ASTRAZENECA PHARM, 2006, PROD INF IR GEF
[3]  
*ASTRAZENECA PHARM, 2007, PROD INF NOV TAM
[4]   Clinically Significant Drug-Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: A Delphi Survey of Oncology Pharmacists [J].
Chan, Alexandre ;
Tan, Seow-Hwei ;
Wong, Chen May ;
Yap, Kevin Yi-Lwern ;
Ko, Yu .
CLINICAL THERAPEUTICS, 2009, 31 :2379-2386
[5]   Oral chemotherapy: Rationale and future directions [J].
DeMario, MD ;
Ratain, MJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (07) :2557-2567
[6]  
*E LILL CO, 2008, PROD INF PROZ FLUOX
[7]   Avoidance of CYP2D6 Inhibitors in Patients Receiving Tamoxifen [J].
Ferraldeschi, Roberta ;
Howell, Sacha J. ;
Thompson, Alastair M. ;
Newman, William G. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) :E584-E585
[8]  
*GLAXOSMITHKLINE, 2009, PROD INF TYK LAP
[9]   Overrides of Medication Alerts in Ambulatory Care [J].
Isaac, Thomas ;
Weissman, Joel S. ;
Davis, Roger B. ;
Massagli, Michael ;
Cyrulik, Adrienne ;
Sands, Daniel Z. ;
Weingart, Saul N. .
ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (03) :305-311
[10]   CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment [J].
Jin, Y ;
Desta, Z ;
Stearns, V ;
Ward, B ;
Ho, H ;
Lee, KH ;
Skaar, T ;
Storniolo, AM ;
Li, L ;
Araba, A ;
Blanchard, R ;
Nguyen, A ;
Ullmer, L ;
Hayden, J ;
Lemler, S ;
Weinshilboum, RM ;
Rae, JM ;
Hayes, DF ;
Flockhart, DA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (01) :30-39